Back to Newsroom

Arena Pharmaceuticals and Eisai Expand Marketing and Supply Agreement for BELVIQ (lorcaserin HCl) to Include Most Countries Worldwide

SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.’s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its parent company Eisai Co., Ltd. The expanded agreement provides Eisai with exclusive commercialization rights for all countries worldwide, except for South Korea, Taiwan, Australia, Israel and New Zealand. This agreement amends and restates the previous agreement that granted Eisai rights to commercialize BELVIQ in most of North and South America. Eisai’s commercialization rights are subject to applicable regulatory approval.